Jenex Corporation, The (V:JEN*CA)
Business Focus: N/A
Feb 07, 2018 07:30 am ET
Jenex Announces Continuation to BC and Name Change to "Therma Bright Inc."
Toronto, Ontario--(Newsfile Corp. - February 7, 2018) - The Jenex Corporation (TSXV: JEN), ("Jenex" or the "Company"), a progressive medical device technology company, announces that it will be continued from the laws of Alberta to the laws of British Columbia under the Business Corporation Act (BC) effective February 8, 2018 (the "Continuation"). The Continuation was approved by the shareholders of the Company at the annual general and special meeting of shareholders held on November 15, 2017 (the "Meeting"). The principal effects of the Continuation are set out in detail in the information circular for the Meeting. Charter documents for the Continuation will be filed on SEDAR at www.sedar.com on February 8, 2018.
Feb 01, 2018 09:00 am ET
Jenex Announces Non-Binding Letter of Intent with Quinsam Capital Corp. for $250,000 Investment to Develop CBD and THC Related Thermal Therapy Technology for Pain Relief and Other Pain Related Applica
Toronto, Ontario--(Newsfile Corp. - February 1, 2018) - The Jenex Corporation (TSXV: JEN) ("Jenex" or the "Company"), a progressive medical device technology company, today is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with Quinsam Capital Corp. Inc. to collaborate on the development of a commercial trademarked product that will combine Jenex's thermal therapy technology with CBD or THC creams, lotions and/or oils (the "CBD/THC Thermal Device(s)"). Jenex and Quinsam propose to collaborate to develop a trademarked thermal therapy device or devices for pain relief, back pain and/or arthritis pain utilizing CBD or THC.
Jan 30, 2018 04:41 pm ET
Jenex Completes Due Diligence on Acquisition Targets
Toronto, Ontario--(Newsfile Corp. - January 30, 2018) - The Jenex Corporation (TSXV: JEN), ("Jenex" or the "Company"), a progressive medical device technology company, today is pleased to announce that further to its news releases on November 2, 2017 and Dec 12, 2017, the Company has now completed and is satisfied with due diligence on two medical device products with established sales and cash flow. The proposed acquisition assets include a consumer medical device for acne and other cosmetic applications that encompass both heat and light therapy. (the "Proposed Acquisitions"). Jenex has agreed with the vendor to now proceed to negotiate the final terms of the definitive asset purchase agreement ("APA") for of the Proposed Acquisitions and expects to close the transaction by February 28th, 2018. The Company intends to finance the Proposed Acquisitions through debt, equity or a combination thereof expected to be announced in the near future. Jenex will announce the vendor and brand names of the Proposed Acquisition once the APA is signed.
Jan 17, 2018 08:08 am ET
The Jenex Corporation Announces Board Change; Appointment of Advisory Board, Debt Settlement and Option Grants
Toronto, Ontario--(Newsfile Corp. - January 17, 2018) - The Jenex Corporation (TSXV: JEN), ("Jenex" or the "Company"), a progressive medical device technology company, today is pleased to announce the appointment of Tim Peterson as a director. In conjunction with this appointment, Tak Wing Law, the Company's Chief Financial Officer, has resigned as interim director.
Jan 08, 2018 04:57 pm ET
Jenex's TherOZap(TM) Technology Indicates Effectiveness in Inhibiting Zika Virus After Pre-Clinical Study
Toronto, Ontario--(Newsfile Corp. - January 8, 2018) - The Jenex Corporation (TSXV: JEN) ("Jenex" or the "Company"), a progressive medical device technology company, today announces that it has received results indicating effectiveness of its TherOZap™ technology in inhibiting the Zika virus.
Dec 12, 2017 09:29 am ET
The Jenex Corporation Announces Graduation to the TSX Venture, Update on Chinese Global Financial Forum and Proposed Acquisition
Toronto, Ontario--(Newsfile Corp. - December 12, 2017) - The Jenex Corporation (NEX: JEN.H) (TSXV: JEN) ("Jenex" or the "Company"), a progressive medical device technology company, today announces that the Company has met the requirements to be listed as a TSX Venture Tier 2 Company. Effective December 13, 2017, the Company's listing will transfer from NEX to TSX Venture, the Company's Tier classification will change from NEX to Tier 2 and the filing and service office will change from NEX to Toronto. Effective at the opening, December 13, 2017, the trading symbol for the Company will change from JEN.H to JEN.
Dec 04, 2017 09:23 am ET
The Jenex Corporation Announces Completion of Debt Settlement, Files TherOZap(TM) Device Patent and Presents at Chinese Global Financial Forum
Toronto, Ontario--(Newsfile Corp. - December 4, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announces that has received both shareholder and NEX Exchange approval and accordingly has closed its debt settlement arrangements with certain insiders and former insiders of the Company and issued an aggregate of 16,008,634 common shares at a deemed price of $0.05/share to settle and extinguish an aggregate of $800,431.70 in outstanding debt owed to the creditors. All shares are subject to a hold period expiring four months plus a day after their date of issuance.
Nov 23, 2017 08:46 am ET
The Jenex Corporation Announces AGM Results and Submits Application to Graduate to TSXV
Toronto, Ontario--(Newsfile Corp. - November 23, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, would like to announce the voting results from its Annual General and Special Meeting of shareholders (the "Meeting") held last week in Toronto, Ontario on November 15, 2017. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 10,439,138, representing 41.26% of the Company's issued and outstanding common shares.
Nov 02, 2017 08:00 am ET
The Jenex Corporation Signs Letter of Intent to Acquire Medical Device Assets
Toronto, Ontario--(Newsfile Corp. - November 2, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announces that it has entered into a non-binding letter of intent ("LOI" or the "Proposed Acquisition") for two medical device products with established sales and cash flow (the "Acquisition Targets"). The Acquisition Targets have been sold worldwide under established brand names. The Acquisition Targets utilize thermal therapy to relieve cosmetic related acne and other topical related applications. The Acquisition Targets will remain undisclosed as the LOI is conditional upon the execution of a definitive share purchase agreement with an anticipated closing date of January 31st, 2018. The Proposed Acquisition will be subject to customary due diligence to be completed by December 31st, 2017.
Oct 12, 2017 02:36 pm ET
IIROC Trading Resumption - JEN.H
VANCOUVER, Oct. 12, 2017 /CNW/ - Trading resumes in:
Oct 12, 2017 01:18 pm ET
IIROC Trade Resumption - The Jenex Corporation
Vancouver, British Columbia--(Newsfile Corp. - October 12, 2017) - Trading resumes in:
Oct 12, 2017 01:12 pm ET
The Jenex Corporation Reports Promising Initial Results on Zika Virus Testing with TherOZap(TM)
Toronto, Ontario--(Newsfile Corp. - October 12, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announces that it has received promising initial results on the Zika virus testing with TherOZap™.
Oct 11, 2017 10:20 am ET
IIROC Trading Halt - JEN.H
VANCOUVER, Oct. 11, 2017 /CNW/ - The following issues have been halted by IIROC:
Oct 11, 2017 09:12 am ET
IIROC Trade Halt - The Jenex Corporation
Vancouver, British Columbia--(Newsfile Corp. - October 11, 2017) - The following issues have been halted by IIROC:
Oct 06, 2017 06:19 pm ET
The Jenex Corporation Announces Grant of Stock Options
Toronto, Ontario--(Newsfile Corp. - October 6, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company").
Oct 02, 2017 05:33 pm ET
The Jenex Corporation Terminates Exclusive License Agreement with Luminar Media Group Inc.
Toronto, Ontario--(Newsfile Corp. - October 2, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the "Company"), a progressive medical device technology company, today announced that it has formally terminated its exclusive agreement dated October 31st, 2016 to distribute TherOZap™ globally outside of Canada (the "Agreement") with Luminar Media Group Inc. ("Luminar"), for reasons of non-performance of fees payable as outlined in the Agreement. Jenex may in the future consider a non-exclusive agreement with Luminar that includes updated deal terms. In addition, Jenex is now free to investigate other international distribution partners in the future.
Nov 03, 2016 10:25 am ET
IIROC Trading Resumption - JEN.H
VANCOUVER, Nov. 3, 2016 /CNW/ - Trading resumes in:
Oct 31, 2016 11:43 am ET
IIROC Trading Halt - JEN.H
VANCOUVER, Oct. 31, 2016 /CNW/ - The following issues have been halted by IIROC:
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.